surmount-1 trial tirzepatide non-diabetic obesity weight loss SURMOUNT-1: Adults achieve of 16% or more at 72 weeks with Tirzepatide: Breakthrough in Obesity and

Patients using GLP-1 medications should watch for hypoglycemia , particularly in conjunction with other diabetes treatments

Keep that lens on everything below

Mounjaro directly targets this gut-brain communication

Semaglutide works by mimicking the action of the natural hormone GLP-1

doi: 10.3389/fendo.2025.1614726 Received 19 April 2025 Accepted 24 September 2025 Published 13 October 2025 Volume 16 - 2025 Edited by Marcia Hiriart, Universidad Nacional Autonoma de Mexico, Mexico Reviewed by Absalon Gutierrez, University of Texas Health Science Center at Houston, United States Mubashshir Ali, University of South Florida, United States Updates Copyright 2025 Wang, Qi, Yang, Yang, Wang, Zhang, Cui, Wang, Wang and Lv